Literature DB >> 17287959

The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation.

Piero Calvini1, Guido Rodriguez, Fabrizio Inguglia, Alessandro Mignone, Ugo Paolo Guerra, Flavio Nobili.   

Abstract

PURPOSE: To design a novel algorithm (BasGan) for automatic segmentation of striatal (123)I-FP-CIT SPECT.
METHODS: The BasGan algorithm is based on a high-definition, three-dimensional (3D) striatal template, derived from Talairach's atlas. A blurred template, obtained by convolving the former with a 3D Gaussian kernel (FWHM = 10 mm), approximates striatal activity distribution. The algorithm performs translations and scale transformation on the bicommissural aligned image to set the striatal templates with standard size in an appropriate initial position. An optimization protocol automatically performs fine adjustments in the positioning of blurred templates to best match the radioactive counts, and locates an occipital ROI for background evaluation. Partial volume effect correction is included in the process of uptake computation of caudate, putamen and background. Experimental validation was carried out by means of six acquisitions of an anthropomorphic striatal phantom. The BasGan software was applied to a first set of patients with Parkinson's disease (PD) versus patients affected by essential tremor.
RESULTS: A highly significant correlation was achieved between true binding potential and measured (123)I activity from the phantom. (123)I-FP-CIT uptake was significantly lower in all basal ganglia in the PD group versus controls with both BasGan and a conventional ROI method used for comparison, but particularly with the former. Correlations with the motor UPDRS score were far more significant with the BasGan.
CONCLUSION: The novel BasGan algorithm automatically performs the 3D segmentation of striata. Because co-registered MRI is not needed, it can be used by all nuclear medicine departments, since it is freely available on the Web.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17287959     DOI: 10.1007/s00259-006-0357-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   10.057


  23 in total

1.  Optimization of automated quantification of 123I-IBZM uptake in the striatum applied to parkinsonism.

Authors:  P E Radau; R Linke; P J Slomka; K Tatsch
Journal:  J Nucl Med       Date:  2000-02       Impact factor: 10.057

2.  Automated stereotactic standardization of brain SPECT receptor data using single-photon transmission images.

Authors:  K Van Laere; M Koole; Y D'Asseler; J Versijpt; K Audenaert; F Dumont; R Dierckx
Journal:  J Nucl Med       Date:  2001-02       Impact factor: 10.057

3.  European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine D(2) receptor ligands.

Authors:  K Tatsch; S Asenbaum; P Bartenstein; A Catafau; C Halldin; L S Pilowsky; A Pupi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-10       Impact factor: 9.236

4.  Partial volume effect correction in SPECT for striatal uptake measurements in patients with neurodegenerative diseases: impact upon patient classification.

Authors:  Marine Soret; Pierre Malick Koulibaly; Jacques Darcourt; Irène Buvat
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-04-26       Impact factor: 9.236

5.  Logistic discriminant parametric mapping: a novel method for the pixel-based differential diagnosis of Parkinson's disease.

Authors:  P D Acton; P D Mozley; H F Kung
Journal:  Eur J Nucl Med       Date:  1999-11

6.  Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years.

Authors:  M Chouker; K Tatsch; R Linke; O Pogarell; K Hahn; J Schwarz
Journal:  Nucl Med Commun       Date:  2001-06       Impact factor: 1.690

7.  Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.

Authors: 
Journal:  JAMA       Date:  2002-04-03       Impact factor: 56.272

8.  The application of statistical parametric mapping to 123I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer's disease and Parkinson's disease.

Authors:  Sean J Colloby; John T O'Brien; John D Fenwick; Michael J Firbank; David J Burn; Ian G McKeith; E David Williams
Journal:  Neuroimage       Date:  2004-11       Impact factor: 6.556

Review 9.  Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee.

Authors:  G Deuschl; P Bain; M Brin
Journal:  Mov Disord       Date:  1998       Impact factor: 10.338

10.  Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies.

Authors:  John T O'Brien; Sean Colloby; John Fenwick; E David Williams; Michael Firbank; David Burn; Dag Aarsland; Ian G McKeith
Journal:  Arch Neurol       Date:  2004-06
View more
  36 in total

Review 1.  SPECT imaging evaluation in movement disorders: far beyond visual assessment.

Authors:  Kosmas Badiavas; Elisavet Molyvda; Ioannis Iakovou; Magdalini Tsolaki; Kyriakos Psarrakos; Nikolaos Karatzas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12-02       Impact factor: 9.236

2.  Is the time ripe to adopt semiquantitative analysis of SPECT evaluation in movement disorders as a standard?

Authors:  Federico Caobelli; Barbara Paghera; Raffaele Giubbini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-06       Impact factor: 9.236

3.  EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2.

Authors:  Koen Van Laere; Andrea Varrone; Jan Booij; Thierry Vander Borght; Flavio Nobili; Ozlem L Kapucu; Zuzana Walker; Kjell Någren; Klaus Tatsch; Jacques Darcourt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02       Impact factor: 9.236

4.  The Role of the Serotonergic System in REM Sleep Behavior Disorder.

Authors:  Dario Arnaldi; Francesco Famà; Fabrizio De Carli; Silvia Morbelli; Michela Ferrara; Agnese Picco; Jennifer Accardo; Alberto Primavera; Gianmario Sambuceti; Flavio Nobili
Journal:  Sleep       Date:  2015-09-01       Impact factor: 5.849

5.  The role of the deep convolutional neural network as an aid to interpreting brain [18F]DOPA PET/CT in the diagnosis of Parkinson's disease.

Authors:  Arnoldo Piccardo; Roberto Cappuccio; Gianluca Bottoni; Diego Cecchin; Luca Mazzella; Alessio Cirone; Sergio Righi; Martina Ugolini; Pietro Bianchi; Pietro Bertolaccini; Elena Lorenzini; Michela Massollo; Antonio Castaldi; Francesco Fiz; Laura Strada; Angelina Cistaro; Massimo Del Sette
Journal:  Eur Radiol       Date:  2021-03-08       Impact factor: 5.315

6.  Impact of quantitative index derived from 123I-FP-CIT-SPECT on reconstruction with correction methods evaluated using a 3D-striatum digital brain phantom.

Authors:  Akihiro Furuta; Hideo Onishi; Noriyasu Yamaki; Nobuhiro Yada; Hizuru Amijima
Journal:  Radiol Phys Technol       Date:  2018-07-16

7.  Feasibility of PET Template-Based Analysis on F-18 FP-CIT PET in Patients with De Novo Parkinson's Disease.

Authors:  Eugene Jeong; Sun Young Oh; Kisoo Pahk; Chan-Nyoung Lee; Kun-Woo Park; Jae Sung Lee; Gi Jeong Cheon; Jae Gol Choe
Journal:  Nucl Med Mol Imaging       Date:  2013-03-26

8.  Brain (18)F-DOPA PET and cognition in de novo Parkinson's disease.

Authors:  Agnese Picco; Silvia Morbelli; Arnoldo Piccardo; Dario Arnaldi; Nicola Girtler; Andrea Brugnolo; Irene Bossert; Lucio Marinelli; Antonio Castaldi; Fabrizio De Carli; Claudio Campus; Giovanni Abbruzzese; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-28       Impact factor: 9.236

9.  Extraction, selection and comparison of features for an effective automated computer-aided diagnosis of Parkinson's disease based on [123I]FP-CIT SPECT images.

Authors:  Francisco P M Oliveira; Diogo Borges Faria; Durval C Costa; Miguel Castelo-Branco; João Manuel R S Tavares
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-12-23       Impact factor: 9.236

10.  EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2.

Authors:  Jacques Darcourt; Jan Booij; Klaus Tatsch; Andrea Varrone; Thierry Vander Borght; Ozlem L Kapucu; Kjell Någren; Flavio Nobili; Zuzana Walker; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.